Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Gastroparesis, Delayed Gastric Emptying
Interventions: Gastric Focused Ultrasound Stimulation; Device
Lead sponsor: Evan (Huiliang) Wang; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Type 2 Diabetes
Interventions: liraglutide, insulin detemir, liraglutide plus insulin detemir; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Renal Impaired, Gilteritinib, Normal Renal Function, Pharmacokinetics of ASP2215
Interventions: Gilteritinib; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Garden Grove, California • Tustin, California • Orlando, Florida

Conditions: Relapsed/Refractory B Cell Malignancies, Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Treatment-Naive B Cell Malignancies
Interventions: TL-895, Navtemadlin; Drug
Lead sponsor: Telios Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 2
States / cities: Columbus, Ohio • Germantown, Tennessee

Conditions: Healthy
Interventions: clopidogrel, Matching placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Seasonal Influenza Preventative Vaccine Pharmacodynamics
Interventions: VXA-A1.1 H1 Tablet Vaccine (small), VXA-A1.1 H1 Tablet Vaccine (large); Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Transgenderism
Interventions: Transdermal patch, Pro-thrombotic markers, Metabolic markers, Hormone Profile, Daily Sublingual Tablet, BID Sublingual Tablet, Spironolactone; Drug · Diagnostic Test
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pre-diabetes, Type II Diabetes, Insulin Resistance
Interventions: Not listed
Lead sponsor: PeriRx; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Type 2
Interventions: Insulin-Levemir, Exenatide-Bayetta, Insulin-Levemir and Exenatide-Bayetta, SenseWear Pro3® armband, DexCom CGM; Drug · Device
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Prediabetes, Cardiovascular Disease
Interventions: Glucose (100g), Glucose (75g), Whole Eggs, Egg Whites, Egg Yolks; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Fasting
Interventions: Desloratadine; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Surgical Site Infection, Skin Cancer, Wound Healing
Interventions: Cyanoacrylate Skin Adhesive, Fast Gut Running Epidermal Suture Closure, Vicryl Rapide Running Epidermal Suture Closure, Prolene Running Epidermal Suture Closure; Device · Procedure
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Minneapolis, Minnesota

Conditions: Insulin Sensitivity
Interventions: Not listed
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Phenylketonuria
Interventions: Kuvan, Diet; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 4 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Malignant Neoplasm
Interventions: questionnaire administration, preventative dietary intervention, laboratory biomarker analysis; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 2 Diabetes Mellitus (T2DM), Pregnancy, Continuous Glucose Monitoring System
Interventions: Continuous glucose monitor, Glucometer; Device
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Sewell, New Jersey • Philadelphia, Pennsylvania

Conditions: Dravet Syndrome
Interventions: EPX-100 (Clemizole Hydrochloride), Placebos; Drug
Lead sponsor: Epygenix; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: Ren-Nu and KetoCitra; Dietary Supplement
Lead sponsor: Richard Fatica; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Carcinoma, Recurrent Prostate Carcinoma
Interventions: Antiandrogen Therapy, Behavioral Intervention, Biospecimen Collection, Cardiac Computerized Tomographic Angiography, Computed Tomography, Electronic Health Record Review, Internet-Based Intervention, Lifestyle Counseling, Medical Device Usage and Evaluation, Nutritional Intervention, Questionnaire Administration, Radiation Therapy, Referral, Semaglutide, Short-Term Fasting, Tirzepatide; Drug · Behavioral · Procedure + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 30 Years to 79 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Healthy
Interventions: LOXO-783; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Fasting
Interventions: a breath analysis using the Aeonose, Aeonose; Other · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 879 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Malignant Melanoma, Neoplasms
Interventions: Tizanidine, Vemurafenib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Pleasant Hill, California • Detroit, Michigan • Durham, North Carolina

Conditions: Impulsive Behavior, Mental Disorders
Interventions: Cognitive Control Training; Other
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Severe Hypertriglyceridemia
Interventions: K-877, Fenofibrate, Placebo (for K-877); Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 129
States / cities: Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 109 more

Search by objective public record fields.

Gastric Focused Ultrasound Stimulation

Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake

A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Food Effect Study on Pharmacodynamic and Bioavailability of Clopidogrel 300/75 mg in Healthy Subjects

Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults

Transgender Estradiol Affirming Therapy

Salivary Transcriptome Biomarkers for Early Diabetes Detection

Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

Cardioprotective Activities Of Whole Eggs On Vascular Endothelial Function In Prediabetic Adults

Bioavailability Study of Dr. Reddy's Desloratadine Tablets, 5 mg Under Fasting Conditions.

Cyanoacrylate Skin Adhesive After Mohs Surgery or Wide Local Excision

Insulin Variance Throughout the Day

Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response

Short-Term Fasting Before Chemotherapy in Treating Patients With Cancer

CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes

Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.

Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants

Electronic Nose Identification of Fasting and Non-fasting Breath Profiles

A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies

Cognitive Control Training for Urgency in a Naturalistic Clinical Setting

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment